Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-661-7661
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees55
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions
What is Ovid Therapeutics' stock symbol?
Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."
How were Ovid Therapeutics' earnings last quarter?
Ovid Therapeutics Inc (NASDAQ:OVID) announced its earnings results on Wednesday, August, 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.42) by $0.08. View Ovid Therapeutics' Earnings History.
When is Ovid Therapeutics' next earnings date?
What price target have analysts set for OVID?
7 equities research analysts have issued 1 year price objectives for Ovid Therapeutics' stock. Their predictions range from $10.00 to $27.00. On average, they expect Ovid Therapeutics' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 527.8% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.
What is the consensus analysts' recommendation for Ovid Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.
Has Ovid Therapeutics been receiving favorable news coverage?
Media headlines about OVID stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ovid Therapeutics earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Ovid Therapeutics.
Are investors shorting Ovid Therapeutics?
Ovid Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 564,500 shares, an increase of 86.7% from the August 30th total of 302,400 shares. Based on an average daily trading volume, of 489,200 shares, the days-to-cover ratio is currently 1.2 days. Currently, 3.1% of the shares of the company are short sold. View Ovid Therapeutics' Current Options Chain.
Who are some of Ovid Therapeutics' key competitors?
Some companies that are related to Ovid Therapeutics include Prothena (PRTA), Kiniksa Pharmaceuticals (KNSA), OptiNose (OPTN), Kindred Biosciences (KIN), CytomX Therapeutics (CTMX), Neptune Wellness Solutions (NEPT), Protagonist Therapeutics (PTGX), Ardelyx (ARDX), Molecular Templates (MTEM), Atreca (BCEL), Avid Bioservices (CDMO), Cyclerion Therapeutics (CYCN), Recro Pharma (REPH), Theratechnologies (THERF) and Urovant Sciences (UROV).
What other stocks do shareholders of Ovid Therapeutics own?
Who are Ovid Therapeutics' key executives?
Ovid Therapeutics' management team includes the folowing people:
- Dr. Jeremy Max Levin, Chairman & CEO (Age 66)
- Dr. Matthew J. During, Founder, Chairman of Scientific Advisory Board & Director (Age 62)
- Ms. Lora Pike, Sr. Director of Investor Relations & PR
- Ms. Ana C. Ward Esq., M.S., M.B.A., Sr. VP, Gen. Counsel & Sec. (Age 50)
- Mr. Thomas Michael Perone, Sr. VP, Gen. Counsel & Sec.
When did Ovid Therapeutics IPO?
(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.
How do I buy shares of Ovid Therapeutics?
Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ovid Therapeutics' stock price today?
One share of OVID stock can currently be purchased for approximately $2.23.
How big of a company is Ovid Therapeutics?
Ovid Therapeutics has a market capitalization of $86.28 million. The company earns $-51,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe.View Additional Information About Ovid Therapeutics.
What is Ovid Therapeutics' official website?
How can I contact Ovid Therapeutics?
Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]
MarketBeat Community Rating for Ovid Therapeutics (NASDAQ OVID)
MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days.
